Publication:
Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study

Loading...
Thumbnail Image

Date

2014-11-02

Authors

Neukam, Karin
Espinosa, Nuria
Merino, Dolores
Rivero-Juárez, Antonio
Carrero, Ana
Ríos, María José
Ruiz-Morales, Josefa
Gómez-Berrocal, Ana
Téllez, Francisco
Díaz-Menéndez, Marta

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

BioMed Central
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Although hepatotoxicity related to antiretroviral treatment (ART) has become less frequent, hepatotoxic events, such as transaminase elevations (TE), are still a matter of concern. RPV/FTC/TDF (EPA) is a new single tablet regimen which is widely used in real life practice. Clinical trials showed an adequate profile of liver safety in the sub-population of HIV/HCV- coinfected patients receiving rilpivirine. However, the number of individuals included in these analyses is low [1]. The aim of this ongoing study is to evaluate the incidence of TE and total bilirubin elevations (TBE) during the first 48 weeks of EPA-based therapy in a large population of HIV/HCV-coinfected subjects outside of clinical trials.

Description

MeSH Terms

Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Pyrroles::Tetrapyrroles::Bile Pigments::Bilirubin
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols
Medical Subject Headings::Diseases::Bacterial Infections and Mycoses::Infection::Coinfection
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents
Medical Subject Headings::Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies
Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence

DeCS Terms

Bilirrubina
Protocolos clínicos
Coinfección
Combinación emtricitabina, rilpivirina y tenofovir

CIE Terms

Keywords

Liver , Emtricitabine, Rilpivirine, Tenofovir Drug Combination , Spain , Tablets , Transaminases

Citation

Neukam K, Espinosa N, Merino D, Rivero-Juárez A, Carrero A, Ríos Mj, et al. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study. J Int AIDS Soc.. 2014, 17(Suppl 3):19631